A Study of HLX105 in Patients With Advanced or Metastatic Solid Tumors
A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX105 (Anti-PD-1 Antibody-IL-2 Variant Fusion Protein) in Advanced/Metastatic Solid Tumors
This is an open-label, first-in-human, Phase 1 study of HLX105, an anti-PD-1 antibody-IL-2 variant fusion protein, in adults with advanced or metastatic solid tumors that have progressed after standard treatment or for which no standard treatment is available. The main purpose is to evaluate the safety and tolerability of HLX105 and determine its maximum tolerated dose. The study will also assess how the body processes HLX105, whether antibodies against HLX105 develop, preliminary antitumor activity, and changes in immune cells and other biomarkers.
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Waihan Ho
- 電話番号:+65-96253244
- メール:Waihan_Ho@henlius.com
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Able to provide written informed consent and comply with study requirements.
- Aged 18-75 years.
- Histologically or cytologically confirmed advanced or metastatic solid tumors following failure of standard treatment, or for which no standard treatment is available.
- At least one measurable extracranial lesion according to RECIST v1.1.
- ECOG performance status of 0-1 and life expectancy greater than 3 months.
- Willing to provide adequate archived tumor tissue or undergo a tumor biopsy.
- Adequate organ function;
- Agreement to comply with protocol-defined contraception requirements during the study and for at least 6 months after the last dose.
Exclusion Criteria:
- Other malignancies within the past 2 years, except protocol-permitted early-stage cancers treated curatively.
- Prior IL-2/IL-15 therapy, or recent anticancer treatment, surgery, or live vaccination within protocol-defined washout periods.
- History of significant immunotherapy-related toxicity, severe allergic reactions, or allergy to HLX105 components.
- History or evidence of interstitial lung disease or other significant pulmonary conditions.
- Active infections, immunodeficiency, prior organ transplantation, or HBV/HCV infection meeting protocol-defined exclusion criteria.
- Significant cardiovascular, cerebrovascular, or thromboembolic disease.
- Brain metastases not meeting protocol-defined stability and eligibility requirements.
- Uncontrolled effusions or unresolved toxicity from prior treatment, except protocol-permitted conditions.
- Pregnancy or breastfeeding.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Dose Escalation
This study is an open-label first-in-human Phase I Clinical trial to evaluate the safety and tolerability of HLX105 with escalated doses in the treatment of participants with advanced/metastatic solid tumors. |
HLX105 will be administered as an intravenous(IV) infusion. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
Dose-limiting toxicity (DLT)
時間枠:The first 21 days starting with the first dose for participants dosed every 3 weeks, and the first 28 days starting with the first dose for participants dosed every 2 weeks.
|
The first 21 days starting with the first dose for participants dosed every 3 weeks, and the first 28 days starting with the first dose for participants dosed every 2 weeks.
|
|
Maximum tolerated dose(MTD)
時間枠:Up to approximately 2 years
|
Up to approximately 2 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
奏功期間(DOR)
時間枠:最長約2年
|
最長約2年
|
|
|
Number of participants with adverse events(AEs)
時間枠:Up to approximately 2 years
|
Up to approximately 2 years
|
|
|
Number of participants with serious adverse events(SAEs)
時間枠:Up to approximately 2 years
|
Up to approximately 2 years
|
|
|
Objective response rate(ORR)
時間枠:Up to approximately 2 years
|
Up to approximately 2 years
|
|
|
Disease control rate(DCR)
時間枠:Up to approximately 2 years
|
Up to approximately 2 years
|
|
|
Progression-free survival(PFS)
時間枠:Up to approximately 2 years
|
Up to approximately 2 years
|
|
|
Overall survival(OS)
時間枠:Up to approximately 2 years
|
Up to approximately 2 years
|
|
|
Cmax
時間枠:Up to approximately 2 years
|
Maximum serum concentration (Cmax) of HLX105 |
Up to approximately 2 years
|
|
Tmax
時間枠:Up to approximately 2 years
|
Time to maximum serum concentration (Tmax) of HLX105 |
Up to approximately 2 years
|
|
T1/2
時間枠:Up to approximately 2 years
|
Half-life (T1/2) of HLX105 |
Up to approximately 2 years
|
|
Percentage of Participants With Anti-HLX105 Antibodies (ADA) and Percentage of Participants With Neutralizing Antibodies (NAb)
時間枠:Up to approximately 2 years
|
Up to approximately 2 years
|
|
|
Change From Baseline in PD-1 Receptor Occupancy on Peripheral Blood T Cells
時間枠:Up to approximately 2 years
|
Receptor occupancy will be expressed as the percentage of PD-1 receptors occupied by the study drug. Changes from baseline will be calculated at each scheduled post-dose assessment. |
Up to approximately 2 years
|
|
Change From Baseline in Peripheral Blood Interferon Gamma Concentration
時間枠:Up to approximately 2 years
|
Up to approximately 2 years
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- HLX105-FIH101
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。